Application Nr Approved Date Route Status External Links
BLA761067 None Subcutaneous None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Ilumya ® Is Indicated For The Treatment Of Adults With Moderate-To-Severe Plaque Psoriasis Who Are Candidates For Systemic Therapy Or Phototherapy. Ilumya Is An Interleukin-23 Antagonist Indicated For The Treatment Of Adults With Moderate-To-Severe Plaque Psoriasis Who Are Candidates For Systemic Therapy Or Phototherapy. ( 1 )

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Tildrakizumab

Comments